Cisplatin/pemetrexed or Carboplatin/pemetrexed

Phase 2Small molecule

MMasonic Cancer Center, University of Minnesota

Cisplatin/pemetrexed or Carboplatin/pemetrexed is one of 38 small molecule programs targeting Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenocarcinomaActive, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

337 competitors in Adenocarcinoma

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 3

47 2

Taxotere

AAvyxa

Phase 3

19 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

19 4

Iressa

AstraZeneca

Phase 3

4 5

Cyramza

Eli Lilly

Phase 3

4 6

Opdivo

Bristol-Myers Squibb

Phase 3

3 7

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

11 8

DATROWAY

Daiichi Sankyo

Phase 3

1 9

Erbitux

IImclone

Phase 3

5 10

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Adenocarcinoma

NCT04105270

Clinical

Trials by Indication[1]

Adenocarcinoma1 trial

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT04105270·82 enrolled

Chemotherapy1 trial

A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.

Not yet recruiting·SShandong Cancer Hospital and Institute·N/A·NCT06649448·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Cisplatin/pemetrexed or Carboplatin/pemetrexed. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cisplatin/pemetrexed or Carboplatin/pemetrexed compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cisplatin/pemetrexed or Carboplatin/pemetrexed. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Masonic Cancer Center, University of Minnesota company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMasonic Cancer Center, University of Minnesota

Cisplatin/pemetrexed or Carboplatin/pemetrexed

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Adenocarcinoma1 trial

Chemotherapy1 trial

References

Drug Info

Quick Facts

Related News